Melodiol Global Health (AU:ME1) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Melodiol Global Health announced that its subsidiary Mernova has seen a substantial increase in revenue, with Q2 2024 orders jumping 25% from Q1 and 33% from the previous year. Mernova not only has a strong start for Q3 with confirmed orders but also made significant strides by launching new products, including its first foray into edibles, and securing a competitive 10% of new product approvals in Nova Scotia. The company’s growth and product expansion underscore its commitment to quality and strong provincial relationships.
For further insights into AU:ME1 stock, check out TipRanks’ Stock Analysis page.